AUS
NZ
UK
CA
USA
IND
Healthcare
Global Cord Blood Gains Analyst Attention for Stem Cell Services
October 29, 2024 08:49 AM PDT| By Team Kalkine MediaHeadlines,Global Cord Blood Gains Analyst Attention,Key Services Offered by Global Cord Blood,Future Prospects of Global Cord Blood,Global Cord Blood,(NYSE:CO),has recently attracted interest from analysts who initiated coverage on the company. The b...
What Are the Implications of GlycoMimetics' Latest Move?
October 29, 2024 06:55 AM PDT| By Team Kalkine MediaHighlights,GlycoMimetics enters into an acquisition agreement with Crescent Biopharma.,The combined entity will focus on innovative treatments for solid tumors.,Significant financing secured to support the development of new therapies.,GlycoMimetics...
Novartis's Q3 net profit increase has resulted in a raised annual sales outlook
October 29, 2024 04:46 AM PDT| By Team Kalkine MediaHighlights,Increased Annual Guidance,: Novartis AG revised its annual sales forecast, anticipating growth in low double-digits, reflecting strong performance in the third quarter.,Strong Q3 Financial Results,: The company reported net earnings of $3....
Pfizer's Q3 earnings preview reveals strong growth potential for PFE stock despite market volatility
October 29, 2024 04:26 AM PDT| By Team Kalkine MediaHighlights,Strong Q3 Projections,: Pfizer anticipates an earnings per share (EPS) of $0.61 and revenue of $14.87 billion for Q3, showcasing significant year-over-year growth.,Optimistic Analyst Insights,: J.P. Morgan's projections suggest potential s...
TransMedics (TMDX) Reports Impressive Q3 2024 Financial Results
October 29, 2024 12:54 AM PDT| By Team Kalkine MediaHighlights:,TransMedics achieves 64% revenue growth, reaching $108.8 million in Q3.,The company reports net income of $4.2 million, a significant turnaround from losses.,Maintains full-year revenue guidance, projecting 76-84% growth for 2024.,TransMe...
What Future Challenges Does Beam Therapeutics Face?
October 28, 2024 07:19 AM PDT| By Team Kalkine MediaHighlights,Beam Therapeutics Inc. demonstrates a price-to-sales ratio that stands out within the healthcare sector.,Recent revenue growth has been strong, contrasting with future expectations.,The outlook for revenue raises questions about the sustai...
How Is Eli Lilly Expanding Mounjaro's Market Presence?
October 28, 2024 05:46 AM PDT| By Team Kalkine MediaHighlights,Eli Lilly,(NYSE:LLY),prepares to launch Mounjaro in Hong Kong by the end of the year.,Mounjaro is positioned to be the first drug of its kind available in the broader China region.,The launch is expected to meet rising demand for effective...
How Is ImmunoPrecise Antibodies Advancing Research on Aging?
October 28, 2024 05:37 AM PDT| By Team Kalkine MediaHighlights,ImmunoPrecise Antibodies,(NASDAQ:IPA),contributes to a significant study on mitochondrial dysfunction.,The research aims to enhance understanding of age-related diseases such as Parkinson's and Alzheimer's.,The company is well-positioned t...
Evoke Pharma Gains Momentum with GIMOTI Study Success
October 28, 2024 05:34 AM PDT| By Team Kalkine MediaHighlights,Evoke Pharma,(NASDAQ:EVOK),reports positive patient outcomes with GIMOTI nasal spray for diabetic gastroparesis.,A real-world study shows significant reductions in healthcare visits for GIMOTI users.,Recognition at ACG 2024 highlights the...
How Will FDA Approval Boost Iterum Therapeutics Stock?
October 28, 2024 05:17 AM PDT| By Team Kalkine MediaHighlights,Iterum Therapeutics announces a conference call to discuss FDA approval of ORLYNVAH.,The treatment marks a significant milestone as the first oral penem approved in the U.S.,ORLYNVAHis aimed at addressing uncomplicated urinary tract infect...
Signaturefd LLC Associated with Growth in Exelixis, Inc. Stake
October 28, 2024 04:31 AM PDT| By Team Kalkine MediaHighlights,Signaturefd LLC increased its holdings in Exelixis, Inc. by 12.2% in the third quarter, reflecting growing confidence in the biotechnology sector.,Institutional ownership of Exelixis remains robust, with 85.27% of shares held by large inve...
Pfizer Management's Turnaround Strategy Being Enhanced Amid Starboard's Watch
October 28, 2024 04:21 AM PDT| By Team Kalkine MediaHighlights,Pfizer's upcoming quarterly financial report is under scrutiny as activist hedge fund Starboard Value intensifies calls for accountability and results.,Analysts seek evidence of improved profitability and revenue growth, particularly from...
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) Announces Encouraging Data for VOQUEZNA® at ACG 2024
October 28, 2024 03:49 AM PDT| By Team Kalkine MediaHighlights:,VOQUEZNA® shows rapid relief for heartburn in Non-Erosive GERD.,ACG Outstanding Research Award recognizes significant findings from the PHALCON-NERD-201 trial.,On-demand dosing could revolutionize treatment options for patients with episo...
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) Advances with IND Clearance for IDE275, a Promising Werner Helicase Inhibitor
October 28, 2024 03:22 AM PDT| By Team Kalkine MediaHighlights:,IDEAYA's IDE275 could become a first-in-class treatment for tumors with microsatellite instability.,The Phase 1 trial aims to target a significant patient population across several cancer types.,Potential for substantial financial milesto...
How Did Dexcom Beat Expectations Despite Revenue Challenges?
October 25, 2024 11:43 AM PDT| By Team Kalkine MediaHighlights,Dexcom reports a decline in U.S. revenue despite strong third-quarter results.,The healthcare sector company maintains its full-year revenue guidance amidst market performance.,Changes in Dexcom’s leadership announced, impacting its commer...
What Is Iterum Therapeutics' Latest FDA Approval About?
October 25, 2024 11:34 AM PDT| By Team Kalkine MediaHighlights,Iterum Therapeutics receives FDA approval for its new drug, ORLYNVAH.,ORLYNVAH targets uncomplicated urinary tract infections in adult women.,The approval marks Iterum’s first FDA-approved product.,Iterum Therapeutics plc, a pharmaceutical...
Tectonic Advisors LLC Secures 9,958 Shares in Gilead Sciences, Inc. (NASDAQ:GILD)
October 25, 2024 04:45 AM PDT| By Team Kalkine MediaHighlights,Tectonic Advisors LLC increased its position in Gilead Sciences, Inc. by 15.1% during the third quarter.,Institutional ownership of Gilead has reached 83.67%, with several firms making notable adjustments to their stakes.,Analysts have rai...
Shareholders in Bio-Rad Laboratories (NYSE:BIO) Experience 58% Decline as Shares Fall 4.6% This Week
October 25, 2024 04:10 AM PDT| By Team Kalkine MediaHighlights,Bio-Rad Laboratories, Inc. has experienced a significant decline in share price, dropping 58% over the past three years.,Recent financial performance indicates a loss over the last twelve months, raising concerns about future profitability...
Position in Natera, Inc. (NASDAQ:NTRA) Strengthened by Zweig DiMenna Associates LLC
October 25, 2024 04:01 AM PDT| By Team Kalkine MediaHighlights,Zweig DiMenna Associates LLC significantly increased its stake in Natera, Inc. by 213% during the third quarter.,Natera's recent earnings report exceeded consensus estimates, showcasing robust revenue growth.,Several analysts have raised t...
Boston Scientific's Strong Performance: A Positive Outlook Ahead
October 24, 2024 10:26 PM PDT| By Team Kalkine MediaHeadlines,Boston Scientific delivers impressive quarterly earnings, surpassing expectations.,Analysts provide optimistic outlooks, adjusting price targets upward.,Strong financial metrics highlight the company's growth potential.,Boston Scientific,(N...
